Psoriasis treatment has been revolutionized by biologic injections targeting IL-17 and IL-23, which can clear skin almost completely for most patients. Newer oral drugs and topical treatments are now expanding options for milder disease and for people who prefer pills over injections.
What's actually going on in research
Trials are testing newer IL-23 and TYK2 inhibitors, oral and topical small-molecule drugs, treatments for psoriatic arthritis, and approaches for difficult areas like the scalp, palms, soles, and genitals. Researchers are also studying long-term safety, pregnancy outcomes, and the link between psoriasis and heart disease.
IL-23 inhibitors
Injections targeting IL-23 produce clear or nearly clear skin in most patients with dosing as infrequent as every three months. Several are now standard.
New oral drugs
TYK2 inhibitors like deucravacitinib and other oral drugs are giving patients pill options that approach biologic-level results without injections.
Beyond skin
Up to a third of people with psoriasis develop psoriatic arthritis. Trials are testing whether early biologic use can prevent joint damage and screening for heart disease.
What to know before you search
Eligibility often depends on body surface area affected, prior treatments, presence of psoriatic arthritis, and other health conditions.
What types of trials are currently open
- New medication trials — Testing biologics and oral drugs for psoriasis, often aiming for clear or near-clear skin.
- Topical trials — Testing newer creams and ointments for milder psoriasis or sensitive areas.
- Treatment for special areas — Studies focused on scalp, palms, soles, nails, and genital psoriasis.
- Therapy strategy trials — Testing how to switch or combine treatments when one stops working.
- Observational studies — Following people with psoriasis to understand long-term safety, joint involvement, and heart disease risk.
Recently added Psoriasis trials
Picankibart in Palmoplantar Pustulosis
1. Study Design This study is designed as a prospective, single-arm, open-label clinical study. It will be conducted by the Department of Dermatology, the First Affiliated Hospital of Air Force Medical University, and plans to enroll 60 eligible subjects. 2. Study Subjects Inclusion Criteria 1. Aged 18-65 years, regardless of gender. 2. Patients with a confirmed diagnosis of palmoplantar pustulosis based on clinical manifestations and/or skin histopathology. 3. Failed treatment with at least one conventional systemic agent (regular administration at standard dosage for 12-24 weeks), or intolerant to adverse reactions. 4. Considered suitable for treatment with Picankibart as assessed by the clinician. 5. Voluntarily participate in the study and provide written informed consent. Exclusion Criteria 1. Patients with active hepatitis B, hepatitis C, or tuberculosis. 2. Pregnant patients or those planning pregnancy within 6 months. 3. Subjects unable to comply with follow-up as required by the study protocol. 4. Other conditions deemed unsuitable for this study. Withdrawal Criteria 1. Subjects may withdraw from the study at any time for any reason. 2. Occurrence of a serious adverse event or intolerable adverse event. 3. Development of any item listed in the exclusion criteria during the study. 4. The investigator may decide subject withdrawal for medical reasons.
Oxidative Stress in Autoimmune Rheumatic Diseases
Rheumatic diseases constitute a group of non-communicable diseases characterized by chronic inflammation. The most common autoimmune rheumatic diseases (ARDs) are rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, myositis, Sjogren's syndrome and systemic scleroderma. These autoimmune disorders lead to joint destruction and adversely influence the human body systemically. One of their characteristics is comorbidity, since patients usually suffer also from other pathologies such as cardiovascular diseases and obesity. In addition, their treatment requires a combination of both biological and conventional pharmaceutical interventions as well as other parameters such as physical activity programs, nutrition, and the use of smart electronic devices. Therefore, the ARDs burden health systems worldwide. Apart from the physiological manifestations of ARDs, specific changes are observed at the cellular and molecular level. A common biochemical/molecular symptom of these diseases is oxidative stress. This condition leads to the disturbance of blood and tissue redox status due to the excessive production of free radicals. Given that free radicals are highly reactive moieties with strong oxidative capacity against biomolecules (i.e., proteins, lipids, DNA), they compromise the efficacy of the intrinsic antioxidant mechanisms and, finally, induce the disruption of redox homeostasis. However, there is no sufficient data linking the levels of redox status of patients with the progression of ARDs over time. Indeed, the onset and symptoms of ARDs are intertwined with the disruption of the patient redox homeostasis and the induction of oxidative stress. Concurrently, the absence of a completely effective pharmaceutical treatment emerges the need for the adoption of novel biomarkers for monitoring the severity of the symptoms and the evolution of ARDs in general. To that end, this study aims at first to investigate the blood redox status of patients with ARDs. Thus, specific redox biomarkers will be evaluated in the blood of patients in three time points (i.e., at Days 1, 180 and 360), and they will be associated with the clinical manifestations of their diseases. The ultimate goal is to clarify whether these biomarkers could putatively exert clinical significance, namely whether they could constitute an additional tool for the monitoring of the progression of these diseases in clinical practice.
Find Psoriasis trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.